GRI Bio(US:GRI) Newsfilter·2025-03-17 12:05Core Insights - GRI Bio, Inc. is advancing its lead program GRI-0621, a treatment for idiopathic pulmonary fibrosis (IPF), with interim data expected in Q2 2025 and topline data in Q3 2025 [1][2][11] - The company reported a net loss of $8.2 million for the fiscal year ended December 31, 2024, with research and development expenses increasing to $3.8 million [6][8] - GRI Bio's cash and cash equivalents as of December 31, 2024, were approximately $5.0 million, expected to fund operations into Q2 2025 [8] Company Overview - GRI Bio is a biotechnology company focused on developing Natural Killer T (NKT) cell modulators for inflammatory, fibrotic, and autoimmune diseases [1][12] - The lead program GRI-0621 is a small molecule RAR-βɣ dual agonist that inhibits human iNKT cell activity, showing promise in improving fibrosis and liver function in preliminary trials [4][12] - The company is also developing a pipeline of novel type 2 diverse NKT agonists for systemic lupus erythematosus and has a library of over 500 proprietary compounds [12] Financial Performance - Research and development expenses increased by $0.6 million from 2023 to 2024, primarily due to the registrational development program for GRI-0621 [6] - General and administrative expenses decreased by $3.7 million from 2023 to 2024, attributed to reduced fees related to a merger with Vallon Pharmaceuticals, Inc. [7] - The company believes its existing cash will be sufficient to fund operations through Q2 2025, including the interim data readout from GRI-0621 [8]